Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for hematological malignancies.

G D Schmidt-Wolf1, I G H Schmidt-Wolf

  • 1Medizinische Klinik und Poliklinik I, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.

Clinical and Experimental Medicine
|May 16, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.

Cancer immunology, immunotherapy : CII·2020
Same author

Cross-sectional increase of adherence to multidisciplinary tumor board decisions.

BMC cancer·2018
Same author

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Leukemia·2015
Same author

[State of the art treatment of progressive or refractory multiple myeloma].

Deutsche medizinische Wochenschrift (1946)·2014
Same author

Hairy cell leukemia: short review, today's recommendations and outlook.

Blood cancer journal·2014
Same author

Sequential Hodgkin's and non-Hodgkin's lymphoma in non-immunocompromised patients.

Annals of hematology·2013

Gene therapy offers a promising approach to treating cancers caused by genetic mutations. This innovative treatment is being explored for various blood cancers and may be most effective in eliminating residual disease post-treatment.

Area of Science:

  • Oncology
  • Genetics
  • Immunology

Background:

  • Cancer arises from genetic mutations, making it a potential target for gene therapy.
  • Gene therapy has been applied to hematological malignancies, including leukemias and lymphomas.
  • Existing applications include graft-versus-host disease and multiple myeloma.

Purpose of the Study:

  • To explore the potential of gene therapy in cancer treatment.
  • To outline various strategies for employing gene therapy against cancer.
  • To identify the most promising applications of gene therapy in oncology.

Main Methods:

  • Gene transfer into hematopoietic stem cells.
  • Modulation of antitumor immune responses.
  • Correction of genetic defects in cancer cells.

Related Experiment Videos

  • Enhancing cancer cell susceptibility to conventional therapies.
  • Increasing resistance of normal host cells to therapies.
  • Cell tracking for therapeutic monitoring.

    • Main Results:

    • Gene therapy is being investigated for leukemias, lymphomas, graft-versus-host disease, and multiple myeloma.
    • Potential applications include immune enhancement, genetic correction, and altering therapy sensitivity.
    • Gene therapy may be crucial for eradicating minimal residual disease.

    Conclusions:

    • Gene therapy holds significant promise for treating genetic-driven cancers, particularly hematological malignancies.
    • Multiple strategies exist for utilizing gene therapy, including immune stimulation and genetic correction.
    • The eradication of minimal residual disease is a key potential benefit of gene therapy in cancer care.